Roche Holding stock: RBC keeps CHF 400.00 target for Roche Holding stock

Published on 10/20/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC keeps a CHF 400.00 target on October 19, 2026. Roche Holding stock costs EUR 417.25 on October 20, 2026 at 3:18 p.m. CEST.

Analyst view and reporting date

RBC Capital kept its Outperform rating and CHF 400.00 target on October 19, 2026.
Roche scheduled its third-quarter sales release for October 22, 2026.
Roche Holding stock costs EUR 417.25 at Lang & Schwarz on October 20, 2026 at 3:18 p.m. CEST.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was assigned an Outperform rating and a CHF 400.00 price target by RBC Capital on October 19, 2026, giving investors a fresh benchmark before the company's next sales update. Roche Holding stock was trading at EUR 417.25 at Lang & Schwarz on October 20, 2026 at 3:18 p.m. CEST.

RBC keeps its CHF 400.00 target

According to Investing.com, RBC Capital retained its Outperform view and CHF 400.00 target. The target stood 2.30 percent above the CHF 391.00 Roche share price on SIX at 3:14 p.m. CEST on October 20, 2026.

The counterpoint came from Jefferies. A report carried by FinanzNachrichten said on October 12, 2026 that Jefferies raised its target from CHF 230.00 to CHF 250.00 while keeping an Underperform rating. The note cited a 40.00 percent valuation premium and highlighted execution by Giredestrant and Fenebrutinib.

Price sits near the yearly high

Roche traded at CHF 391.00 on SIX on October 20, 2026 at 3:14 p.m. CEST, up 1.40 percent from CHF 385.60. Its 52-week range was CHF 270.80 to CHF 393.00, putting the latest SIX price 0.51 percent below the high. Roche's market capitalization was CHF 266.0 billion at the same snapshot, while its price-to-earnings ratio was 25.22.

What comes on October 22?

Roche's investor calendar lists its third-quarter sales release for October 22, 2026, at 2:00 p.m. CEST in Basel. The date is the next scheduled company event named on Roche. The same investor page reports 2025 core earnings per share growth of 11.00 percent at constant exchange rates and 39 million patients treated with Roche medicines in fiscal year 2025.

Comparison with peers

Roche Holding: up 1.40 percent, price-to-earnings ratio 25.22, market capitalization CHF 266.0 billion.

Novartis (SIX, CHF): up 1.06 percent, price-to-earnings ratio 23.28, market capitalization CHF 238.6 billion.

Sanofi (Euronext Paris, EUR): up 1.65 percent, price-to-earnings ratio 22.27, market capitalization EUR 86.5 billion.

Roche stock stays close to its high

For investors, the key contrast is the narrow gap between Roche's SIX price and its 52-week high, alongside RBC's CHF 400.00 target and Jefferies' lower CHF 250.00 view. Roche Holding was trading at EUR 417.25 at Lang & Schwarz on October 20, 2026 at 3:18 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.